scispace - formally typeset
E

Eric J. Topol

Researcher at Scripps Health

Publications -  1406
Citations -  162373

Eric J. Topol is an academic researcher from Scripps Health. The author has contributed to research in topics: Myocardial infarction & Angioplasty. The author has an hindex of 193, co-authored 1373 publications receiving 151025 citations. Previous affiliations of Eric J. Topol include Loyola University Chicago & Cleveland Clinic.

Papers
More filters
Journal ArticleDOI

Neurosurgical evacuation of intracranial hemorrhage after thrombolytic therapy for acute myocardial infarction: Experience from the GUSTO-I Trial☆☆☆★★★♢

TL;DR: Data indicate that neurosurgical evacuation may be associated with improved clinical outcomes in patients receiving thrombolytic therapy for acute myocardial infarction, and Physicians treating such patients should consider early neuros surgical consultation and intervention.
Journal ArticleDOI

Triple antiplatelet therapy does not increase femoral access bleeding with vascular closure devices.

TL;DR: In contemporary percutaneous coronary intervention practice, with appropriate patient selection, a CD can be safely utilized despite aggressive polypharmacy for procedural anticoagulation.
Journal ArticleDOI

Mortality, kidney disease and cardiac procedures following acute coronary syndrome

TL;DR: The risk of death greatly outweighed the risk of reduced eGFR or development of ESRD following ACS and the occurrence of cath +/- PCI was not associated with significant differences in long-term renal function.
Journal ArticleDOI

Cardiovascular and nervous system changes during meditation

TL;DR: The first study to investigate neurological and cardiovascular responses during meditation in both novice and experienced meditators using novel, wearable, wireless devices supports the need for further investigation of the short- and long-term cardiovascular effects of mental calm and individualized ways to achieve it.
Journal ArticleDOI

Emerging genomic applications in coronary artery disease.

TL;DR: Loss-of-function variants in the hepatic cytochrome 2C19 system have now been found to be the predominant genetic mediators of clopidogrel antiplatelet response, with variant carriers having a >3-fold increase in risk for stent thrombosis.